Business
Cancellation of Treasury Shares & TVR
EKF Diagnostics Holdings plc has completed the cancellation of 13,710,698 ordinary shares, acquired through its share buyback programme, effective December 2, 2025. Following this cancellation, the company's total issued share capital stands at 435,383,092 ordinary shares, with no shares held in treasury. This updated figure of 435,383,092 voting rights will serve as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules. Disclaimer*
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n\nEKF Diagnostics Holdings plc\n(\"EKF\" or the \"Company\")\n \nCancellation of Treasury Shares & TVR \n \nEKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 24 November 2025, in connection with the Company's share buyback programme totalling 13,710,698 ordinary shares of 1p each in the capital of the Company (\"Ordinary Shares\"). The Company confirms that these Ordinary Shares, have now been cancelled with effect from 02 December 2025, in accordance with the provisions of section 729 of the Companies Act 2006 (the \"Cancellation\").\n \n \nFurther details in connection with the Cancellation can be found below:\n \n\n\n\n\nDate of Cancellation\n\n\n02 December 2025\n\n\n\n\nNumber of Ordinary Shares cancelled pursuant to the share buyback programme\n\n\n13,710,698\n\n\n\n\nTotal number of Ordinary Shares cancelled\n\n\n13,710,698\n\n\n\n\nFollowing Cancellation, the Company's total issued share capital consists of 435,383,092 Ordinary Shares with one voting right per share. The Company will not hold any Ordinary Shares in treasury.\nTherefore, the total number of voting rights in the Company will be of 435,383,092.\nThe above figure of 435,383,092 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.\n \n\n\n\n\nEKF Diagnostics Holdings plc\n\n\nwww.ekfdiagnostics.com\n\n\n\n\nJulian Baines, Executive Chair\n\n\n Via Walbrook PR\n\n\n\n\nGavin Jones, Chief Executive Officer\n\n\n \n\n\n\n\n\n\n\nTel: +44 (0)20 7496 3000\n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\n \n\n\n\n\nPhil Davies / Oliver Platts\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n \n\n \n \nAbout EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)\n \nEKF is an AIM-listed global diagnostics business focussed on:\n \n· Point-of-Care analysers in the key areas of Hematology and Diabetes.\n· Life S...